Trials

375 trials

No trials match. Try "All" under Status, or clear the gene filter.

• Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

  ● Recruiting now Phase 4 Drug / neuroprotection

  Tom Hühne. Germany

• Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

  ● Recruiting now Phase 3 RNA / antisense

  Laboratoires Thea. Gene: CEP290. Australia, Belgium, Brazil, Canada and 6 more

• A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

  ● Recruiting now Phase 3 Drug / neuroprotection

  Nacuity Pharmaceuticals, Inc.. Not gene-specific. United States

• Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

  ● Recruiting now Phase 2 / Phase 3 Optogenetics, Gene therapy

  Ray Therapeutics, Inc.. Not gene-specific. United States

• Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

  ● Recruiting now Phase 1 / Phase 2 Gene therapy

  AAVantgarde Bio Srl. Gene: MYO7A. Italy, United Kingdom

• Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

  ● Recruiting now Phase 1 / Phase 2 Cell therapy

  Ace Cells Lab Limited. Egypt

• Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

  ● Recruiting now Phase 1 / Phase 2 Gene editing, Gene therapy

  Ascidian Therapeutics, Inc. United States

• BS01 in Patients With Retinitis Pigmentosa

  ● Recruiting now Phase 1 / Phase 2 Optogenetics, Gene therapy

  Bionic Sight LLC. United States

• A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

  ● Recruiting now Phase 1 / Phase 2 Gene therapy, Cell therapy

  BlueRock Therapeutics. United States

• Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

  ● Recruiting now Phase 1 / Phase 2 Gene editing, Gene therapy

  Chigenovo Co., Ltd. Gene: RHO. China

• A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

  ● Recruiting now Phase 2 Optogenetics

  Kiora Pharmaceuticals, Inc.. Australia

• Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa

  ● Recruiting now Phase 1 / Phase 2 Cell therapy

  Mahidol University. Thailand

• A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

  ● Recruiting now Phase 1 / Phase 2 Drug / neuroprotection

  Octant, Inc.. Gene: RHO. United States

• Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

  ● Recruiting now Phase 1 / Phase 2 Gene therapy

  Opus Genetics, Inc. Gene: LCA5. United States

• Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

  ● Recruiting now Phase 1 / Phase 2 Gene therapy

  Opus Genetics, Inc. Gene: RDH12. United States

• Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

  ● Recruiting now Phase 1 / Phase 2 Gene therapy

  SparingVision. Belgium, France, Ireland

• A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

  ● Recruiting now Phase 1 / Phase 2 Gene therapy, Cell therapy

  Sumitomo Pharma America, Inc.. United States

• Disulfiram for Treatment of Retinal Degeneration

  ● Recruiting now Phase 1 / Phase 2 Drug / neuroprotection

  University of Washington. United States

• Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa

  ● Recruiting now Phase 1 Drug / neuroprotection

  Kyushu University. Japan

• An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

  ● Recruiting now Phase 1 Drug / neuroprotection

  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. China

• Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

  ● Recruiting now Phase 1 Supplement / diet

  Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm). Australia, China, United States

• Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION

  ● Recruiting now Phase 1 Cell therapy

  The Foundation for Orthopaedics and Regenerative Medicine. Greece, United States

• The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

  ● Recruiting now Phase 1 Drug / neuroprotection

  University of Rochester. United States

• Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

  ● Recruiting now Phase 1 Gene therapy

  VeonGen Therapeutics GmbH. Gene: CNGA1. Germany

• Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

  ● Recruiting now Early Phase 1 Optogenetics, Gene therapy

  Augelux Therapeutics. Not gene-specific. China

• First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration

  ● Recruiting now Early Phase 1 Gene therapy

  Axovia Therapeutics. Gene: BBS1. United Kingdom

• Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

  ● Recruiting now Early Phase 1 Gene therapy

  Frontera Therapeutics. Gene: RPGR. China

• Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy

  ● Recruiting now Early Phase 1 Drug / neuroprotection

  Peking Union Medical College Hospital. Gene: RLBP1. China

• Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

  ● Recruiting now Early Phase 1 Gene editing, Gene therapy

  Peking University Third Hospital. Gene: RHO. China

• A Study of LX107 Gene Therapy in AIPL1-IRD Patients

  ● Recruiting now Early Phase 1 Gene therapy

  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Gene: AIPL1. China

• Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

  ● Recruiting now Observational Natural history / observational

  Ascidian Therapeutics, Inc. United States

• Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

  ● Recruiting now Observational Natural history / observational

  Assistance Publique - Hôpitaux de Paris. France

• High Resolution, High-speed Multimodal Ophthalmic Imaging

  ● Recruiting now N/A Device

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Natural History Study of Usher Syndrome ( Light4Deaf )

  ● Recruiting now Observational Natural history / observational

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A

  ● Recruiting now Observational Natural history / observational

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. Gene: MYO7A. France

• Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

  ● Recruiting now N/A Other

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• ARPKD Database Study

  ● Recruiting now Observational Natural history / observational

  Children's Hospital of Philadelphia. United States

• North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

  ● Recruiting now Observational Natural history / observational

  Columbia University. Canada, United States

• Study of BEST1 Vitelliform Macular Dystrophy

  ● Recruiting now Observational Natural history / observational

  Columbia University. Gene: BEST1. France, Germany, United States

• Pilot Study of AuTNA I

  ● Recruiting now N/A Gene therapy, Retinal implant

  Eye & ENT Hospital of Fudan University. China

• Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

  ● Recruiting now N/A Device

  Fondazione G.B. Bietti, IRCCS. Italy

• Adaptive Optics Imaging of Outer Retinal Diseases

  ● Recruiting now Observational Natural history / observational

  Food and Drug Administration (FDA). United States

• Inherited Retinal Degenerative Disease Registry

  ● Recruiting now Observational Natural history / observational

  Foundation Fighting Blindness. United States

• Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases

  ● Recruiting now Observational Natural history / observational

  Hadassah Medical Organization. Israel

• EyeConic: Qualification for Cone-Optogenetics

  ● Recruiting now Observational Natural history / observational

  Institute of Molecular and Clinical Ophthalmology Basel. Not gene-specific. China, Germany, Hungary, Italy and 3 more

• Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

  ● Recruiting now Observational Natural history / observational

  Jaeb Center for Health Research. Australia, Belgium, Brazil, Canada and 10 more

• Global Registry and Natural History Study for Mitochondrial Disorders

  ● Recruiting now Observational Natural history / observational

  LMU Klinikum. Austria, Germany, Italy

• Stem Cell Ophthalmology Treatment Study II

  ● Recruiting now N/A Cell therapy

  MD Stem Cells. Austria, United Arab Emirates, United States

• Clinical Registry Investigating Bardet-Biedl Syndrome

  ● Recruiting now Observational Natural history / observational

  Marshfield Clinic Research Foundation. United States

• Cell Collection to Study Eye Diseases

  ● Recruiting now Observational Natural history / observational

  National Eye Institute (NEI). United States

• Rod and Cone Mediated Function in Retinal Disease

  ● Recruiting now Observational Natural history / observational

  National Eye Institute (NEI). United States

• A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

  ● Recruiting now Observational Natural history / observational

  National Human Genome Research Institute (NHGRI). Gene: IMPDH1. United States

• Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

  ● Recruiting now Observational Natural history / observational

  Okuvision GmbH. Germany

• Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

  ● Recruiting now Observational Natural history / observational

  Ray Therapeutics, Inc.. United States

• Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

  ● Recruiting now Observational Natural history / observational

  Ray Therapeutics, Inc.. United States

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  ● Recruiting now Observational Natural history / observational

  Sanford Health. Gene: CRB1. United States

• Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

  ● Recruiting now N/A Retinal implant

  Science Corporation. Australia

• Natural History Study of Patients With EYS-Associated RP

  ● Recruiting now Observational Natural history / observational

  Sensor Technology for Deafblind. Gene: EYS. Russia

• Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer

  ● Recruiting now Observational Natural history / observational

  Sheba Medical Center. Israel

• Natural History Study of Advanced RCD

  ● Recruiting now N/A Natural history / observational

  SparingVision. Belgium, France, Ireland

• Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents

  ● Recruiting now Observational Natural history / observational

  University College, London. Gene: RPE65, RPGR. Germany, United Kingdom, United States

• COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

  ● Recruiting now N/A Other

  University Hospital, Strasbourg, France. France

• Retinal Imaging in Patients With Inherited Retinal Degenerations

  ● Recruiting now Observational Natural history / observational

  University of California, San Francisco. United States

• InsightRP2 Registry

  ● Recruiting now Observational Natural history / observational

  University of Göttingen. Gene: RP2. Germany

• Experimental and Clinical Studies of Retinal Stimulation

  ● Recruiting now N/A Retinal implant

  University of Michigan. United States

• High Resolution Retinal Imaging

  ● Recruiting now Observational Natural history / observational

  University of Pennsylvania. United States

• Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment

  ● Recruiting now N/A Electrical stimulation

  University of Waterloo. Canada

• Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

  ● Recruiting now N/A Other

  Zhongshan Ophthalmic Center, Sun Yat-sen University. China

• GROWing Up With Rare GENEtic Syndromes

  ● Recruiting now Observational Natural history / observational

  dr. Laura C. G. de Graaff-Herder. Netherlands

• 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

  Not yet recruiting Phase 3 Drug / neuroprotection

  Nacuity Pharmaceuticals, Inc.. Not gene-specific

• Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

  Not yet recruiting Phase 2 / Phase 3 Cell therapy

  PT. Prodia Stem Cell Indonesia. Indonesia

• A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

  Not yet recruiting Phase 3 Drug / neuroprotection

  Zhongshan Ophthalmic Center, Sun Yat-sen University. China

• Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

  Not yet recruiting Phase 1 / Phase 2 Optogenetics, Gene therapy

  Augelux Therapeutics. Not gene-specific

• Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

  Not yet recruiting Phase 2 RNA / antisense

  Laboratoires Thea. Gene: USH2A

• The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa

  Not yet recruiting Phase 1 / Phase 2 Drug / neuroprotection

  Sheba Medical Center. Israel

• Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

  Not yet recruiting Phase 2 Drug / neuroprotection

  Yana Najjar. Gene: RP2. United States

• Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa

  Not yet recruiting Phase 1 Drug / neuroprotection

  Suzhou UgeneX Therapeutics Co., Ltd.

• UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

  Not yet recruiting Early Phase 1 Gene therapy

  Suzhou UgeneX Therapeutics Co., Ltd.. China

• Functional Assessments in Vision Impairment

  Not yet recruiting Observational Natural history / observational

  Center for Eye Research Australia. Australia

• A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

  Not yet recruiting Observational Natural history / observational

  IRCCS Ospedale San Raffaele. Gene: USH2A

• Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations

  Not yet recruiting Observational Natural history / observational

  IRCCS San Raffaele. Gene: BEST1, PRPH2, RPE65, RPGR, USH2A. Italy

• Wide Field OCTA in Ocular Diseases

  Not yet recruiting Observational Natural history / observational

  IRCCS San Raffaele

• Retinal Investigation Using Optos OCT Device

  Not yet recruiting N/A Device

  Optos, PLC

• Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

  Not yet recruiting Observational Natural history / observational

  PT. Prodia Stem Cell Indonesia. Indonesia

• An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

  Not yet recruiting N/A Gene therapy

  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Gene: RPE65

• Non-invasive Ultrasound Retinal Stimulation for Vision Restoration

  Not yet recruiting N/A Device

  University of Southern California

• A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

  Enrolling by invitation Phase 2 Gene therapy

  Beacon Therapeutics. Gene: RPGR. United States

• 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients

  Enrolling by invitation Phase 1 / Phase 2 Supplement / diet, Drug / neuroprotection

  Sheba Medical Center. Israel

• Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1

  Enrolling by invitation Early Phase 1 RNA / antisense

  University of Colorado, Denver. United States

• Longitudinal Study of a Bionic Eye

  Enrolling by invitation Observational Natural history / observational

  Center for Eye Research Australia. Australia

• Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa

  Enrolling by invitation N/A Device

  Marta P. Wiącek. Poland

• A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

  Enrolling by invitation Observational Natural history / observational

  Nanoscope Therapeutics Inc.. Not gene-specific. India

• Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients

  Enrolling by invitation Observational Natural history / observational

  University Medical Center Goettingen. Not gene-specific. Germany

• A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

  Underway, not enrolling Phase 2 / Phase 3 Gene therapy

  Beacon Therapeutics. Gene: RPGR. Australia, Canada, United Kingdom, United States

• Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

  Underway, not enrolling Phase 3 Gene therapy

  Innostellar Biotherapeutics Co.,Ltd. Gene: RPE65. China

• Oral N-acetylcysteine for Retinitis Pigmentosa

  Underway, not enrolling Phase 3 Drug / neuroprotection

  Johns Hopkins University. Not gene-specific. Austria, Canada, Germany, Netherlands and 3 more

• Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  Underway, not enrolling Phase 3 Gene therapy

  MeiraGTx Ocular UK Ltd. Gene: RPGR. Belgium, Canada, Denmark, France and 7 more

• A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

  Underway, not enrolling Phase 3 Gene therapy

  MeiraGTx Ocular UK Ltd. Gene: RPGR. Japan

• A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

  Underway, not enrolling Phase 3 Gene therapy

  Ocugen. Not gene-specific. Canada, United States

• A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

  Underway, not enrolling Phase 2 / Phase 3 RNA / antisense

  ProQR Therapeutics. Gene: CEP290. Belgium, Brazil, Canada, France and 5 more

• Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

  Underway, not enrolling Phase 3 Gene therapy

  Spark Therapeutics, Inc.. Gene: RPE65. United States

• 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  4D Molecular Therapeutics. Gene: RPGR. United States

• Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  Atsena Therapeutics Inc.. Gene: GUCY2D. United States

• Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  Beacon Therapeutics. Gene: RPGR. United States

• A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

  Underway, not enrolling Phase 2 Gene therapy

  Beacon Therapeutics. Gene: RPGR. United States

• A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

  Underway, not enrolling Phase 2 Gene therapy

  Beacon Therapeutics. Gene: RPGR. United States

• Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation

  Underway, not enrolling Phase 1 / Phase 2 Cell therapy

  Centre d'Etude des Cellules Souches. France

• Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases

  Underway, not enrolling Phase 1 / Phase 2 Drug / neuroprotection

  Centro de Pesquisa Rubens Siqueira. Brazil

• Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

  Underway, not enrolling Phase 1 / Phase 2 Optogenetics, Gene therapy

  GenSight Biologics. Not gene-specific. France, United Kingdom, United States

• Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  Innostellar Biotherapeutics Co.,Ltd. Gene: RPE65. China

• Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

  Underway, not enrolling Phase 2 RNA / antisense

  Laboratoires Thea. Gene: USH2A. Belgium, Brazil, Canada, Denmark and 6 more

• A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

  Underway, not enrolling Phase 2 Gene therapy

  MeiraGTx Ocular UK Ltd. Gene: RPGR. United Kingdom, United States

• Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  Ocugen. Not gene-specific. United States

• A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

  Underway, not enrolling Phase 1 / Phase 2 RNA / antisense

  PYC Therapeutics. Gene: PRPF31. United States

• A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

  Underway, not enrolling Phase 1 / Phase 2 RNA / antisense

  ProQR Therapeutics. Gene: RHO. United States

• Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases

  Underway, not enrolling Phase 1 / Phase 2 Drug / neuroprotection

  Rubens Camargo Siqueira. Brazil

• PDE6A Gene Therapy for Retinitis Pigmentosa

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  STZ eyetrial. Gene: PDE6A. Germany

• A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

  Underway, not enrolling Phase 2 Drug / neuroprotection

  Sanofi. France, United States

• Promising ROd-cone DYstrophy Gene therapY

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  SparingVision. Gene: PDE6A, PDE6B, RHO. France, United States

• Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

  Underway, not enrolling Phase 1 / Phase 2 Gene therapy

  Spark Therapeutics, Inc.. Gene: RPE65. United States

• Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

  Underway, not enrolling Phase 2 Cell therapy

  jCyte, Inc. Not gene-specific. United States

• CNS10-NPC for the Treatment of RP

  Underway, not enrolling Phase 1 Gene therapy, Cell therapy

  Cedars-Sinai Medical Center. United States

• Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

  Underway, not enrolling Phase 1 Gene therapy

  Innostellar Biotherapeutics Co.,Ltd. Gene: RPE65. China

• FIGHT-RP 1 Extension Study

  Underway, not enrolling Phase 1 Drug / neuroprotection

  Johns Hopkins University. Not gene-specific. United States

• Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

  Underway, not enrolling Phase 1 Gene therapy, Cell therapy

  Qi Zhou. China

• Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

  Underway, not enrolling Phase 1 Optogenetics, Gene therapy

  Ray Therapeutics, Inc.. Not gene-specific. United States

• Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

  Underway, not enrolling Phase 1 Cell therapy

  University of California, Davis. United States

• Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

  Underway, not enrolling Early Phase 1 Gene therapy

  Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Gene: RPE65. China

• Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

  Underway, not enrolling Observational Natural history / observational

  Genentech, Inc.. Gene: RPE65

• Psychotherapy Group for Parents of Children With LCA

  Underway, not enrolling N/A Other

  Instituto de Genética Ocular. Brazil

• Rate of Progression in USH2A-related Retinal Degeneration

  Underway, not enrolling Observational Natural history / observational

  Jaeb Center for Health Research. Gene: USH2A. Canada, France, Germany, Netherlands and 2 more

• Rate of Progression in EYS Related Retinal Degeneration

  Underway, not enrolling Observational Natural history / observational

  Jaeb Center for Health Research. Gene: EYS. Canada, Finland, France, Germany and 3 more

• Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

  Underway, not enrolling Observational Natural history / observational

  Jaeb Center for Health Research. Gene: PCDH15. Canada, France, Germany, Israel and 4 more

• Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

  Underway, not enrolling Observational Natural history / observational

  Nanoscope Therapeutics Inc.. Not gene-specific. Puerto Rico, United States

• Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

  Underway, not enrolling N/A Electrical stimulation

  Nova Southeastern University. United States

• Natural History Study of Retinitis Pigmentosa Type 11

  Underway, not enrolling Observational Natural history / observational

  Oslo University Hospital. Gene: PRPF31. Norway

• Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

  Underway, not enrolling Observational Natural history / observational

  PYC Therapeutics. Gene: PRPF31. Australia, United States

• Early Check: Expanded Screening in Newborns

  Underway, not enrolling Observational Natural history / observational

  RTI International. United States

• Early Genetic Identification of Obesity

  Underway, not enrolling Observational Natural history / observational

  Rolfs Consulting und Verwaltungs-GmbH (RCV). Germany

• Prospective Natural History Study of Retinitis Pigmentosa

  Underway, not enrolling N/A Natural history / observational

  SparingVision. Gene: PDE6A, PDE6B, RHO. France, United States

• A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

  Underway, not enrolling Observational Natural history / observational

  Sumitomo Pharma America, Inc.. United States

• Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa

  Underway, not enrolling Observational Natural history / observational

  University Hospital Tuebingen. Gene: PDE6A, PDE6B, RHO. Germany

• The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction

  ✓ Completed Phase 4 Other

  Aurolab. India

• Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

  ✓ Completed Phase 3 Cell therapy

  Ankara Universitesi Teknokent. Turkey (Türkiye)

• Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision

  ✓ Completed Phase 3 Cell therapy

  Ankara Universitesi Teknokent. Turkey (Türkiye)

• Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

  ✓ Completed Phase 3 Supplement / diet

  Carol Weigel DiFranco. United States

• CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration

  ✓ Completed Phase 3 Gene therapy

  Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Italy

• Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

  ■ Terminated Phase 2 / Phase 3 RNA / antisense

  Laboratoires Thea. Gene: USH2A. Germany, Netherlands, United Kingdom, United States

• Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

  ■ Terminated Phase 2 / Phase 3 RNA / antisense

  Laboratoires Thea. Gene: USH2A. United Kingdom, United States

• Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

  ■ Terminated Phase 2 / Phase 3 Drug / neuroprotection

  Liminal BioSciences Ltd.. United Kingdom

• Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  ✓ Completed Phase 3 Gene therapy

  MeiraGTx Ocular UK Ltd. Gene: RPGR. Belgium, Canada, Denmark, France and 7 more

• Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa

  ✓ Completed Phase 3 Supplement / diet

  National Eye Institute (NEI)

• Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

  ✓ Completed Phase 3 Supplement / diet

  National Eye Institute (NEI). United States

• Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

  ✓ Completed Phase 3 Gene therapy

  NightstaRx Ltd, a Biogen Company. Gene: CHM, RPGR. Brazil, Canada, Denmark, Finland and 5 more

• An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.

  Status unknown Phase 2 / Phase 3 RNA / antisense

  ProQR Therapeutics. Gene: CEP290. Belgium, Brazil, Canada, Germany and 3 more

• Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa

  ■ Terminated Phase 3 Drug / neuroprotection

  R-Tech Ueno, Ltd.. Japan

• Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

  ✓ Completed Phase 3 Drug / neuroprotection

  Rhythm Pharmaceuticals, Inc.. Canada, France, Puerto Rico, Spain and 2 more

• Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

  ✓ Completed Phase 3 Drug / neuroprotection

  Rhythm Pharmaceuticals, Inc.. Australia, Spain, United Kingdom, United States

• Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

  ✓ Completed Phase 3 Drug / neuroprotection

  Rhythm Pharmaceuticals, Inc.. Canada, Germany, Netherlands, Puerto Rico and 2 more

• The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa

  Status unknown Phase 2 / Phase 3 Cell therapy

  TC Erciyes University. Turkey (Türkiye)

• AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Optogenetics, Gene therapy

  AbbVie. Not gene-specific. United States

• Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Cell therapy

  Acibadem University. Turkey (Türkiye)

• A Study in Subjects With Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Aldeyra Therapeutics, Inc.. United States

• An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Drug / neuroprotection

  Allergan. France, Germany, Portugal, United States

• Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  Beacon Therapeutics. Gene: RPE65. United States

• Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa

  Status unknown Phase 2 Drug / neuroprotection

  Beirut Eye Specialist Hospital. Lebanon

• A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  Biogen. Gene: RPGR. United Kingdom, United States

• Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa

  Status unknown Phase 1 / Phase 2 Cell therapy

  Chaitanya Hospital, Pune. India

• Sildenafil for Treatment of Choroidal Ischemia

  ✓ Completed Phase 2 Drug / neuroprotection

  Columbia University. United States

• A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

  ✓ Completed Phase 1 / Phase 2 Drug / neuroprotection

  Dompé Farmaceutici S.p.A. Italy

• Single Ascending Dose Study in Participants With LCA10

  Status unknown Phase 1 / Phase 2 Gene editing, Gene therapy

  Editas Medicine, Inc.. Gene: CEP290. United States

• Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

  ■ Terminated Phase 1 / Phase 2 Drug / neuroprotection

  Endogena Therapeutics, Inc. United States

• Trial of Oral Valproic Acid for Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Foundation Fighting Blindness. United States

• Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

  Status unknown Phase 1 / Phase 2 Gene therapy

  Frontera Therapeutics. Gene: RPGR. China

• Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

  Status unknown Phase 1 / Phase 2 Gene therapy

  HuidaGene Therapeutics Co., Ltd.. Gene: RPE65. China, United States

• Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)

  Status unknown Phase 2 Gene therapy, Cell therapy

  Jinnah Burn and Reconstructive Surgery Centre, Lahore. Pakistan

• A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

  ✓ Completed Phase 1 / Phase 2 Optogenetics

  Kiora Pharmaceuticals, Inc.. Australia

• Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

  ✓ Completed Phase 1 / Phase 2 RNA / antisense

  Laboratoires Thea. Gene: CEP290. Belgium, United States

• Extension Study to Study PQ-110-001 (NCT03140969)

  ■ Terminated Phase 1 / Phase 2 RNA / antisense

  Laboratoires Thea. Gene: CEP290. Belgium, United States

• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

  ■ Terminated Phase 2 RNA / antisense

  Laboratoires Thea. Gene: USH2A. Canada, France, United States

• Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  MeiraGTx UK II Ltd. Gene: RPE65. United Kingdom, United States

• Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  MeiraGTx UK II Ltd. Gene: RPGR. United Kingdom, United States

• Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

  ✓ Completed Phase 2 Drug / neuroprotection

  Moorfields Eye Hospital NHS Foundation Trust. United Kingdom

• Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

  ✓ Completed Phase 1 / Phase 2 Drug / neuroprotection

  Nacuity Pharmaceuticals, Inc.. Not gene-specific. Australia

• Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Optogenetics, Gene therapy

  Nanoscope Therapeutics Inc.. Not gene-specific. India

• Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

  ✓ Completed Phase 2 Optogenetics, Gene therapy

  Nanoscope Therapeutics Inc.. Not gene-specific. Puerto Rico, United States

• Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  Nantes University Hospital. Gene: RPE65. France

• Effects of Lutein in Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Supplement / diet, Drug / neuroprotection

  National Center for Complementary and Integrative Health (NCCIH). United States

• Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Drug / neuroprotection

  National Eye Institute (NEI). United States

• Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

  ■ Terminated Phase 1 / Phase 2 Drug / neuroprotection

  National Eye Institute (NEI). Gene: NR2E3. United States

• A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Neurotech Pharmaceuticals. United States

• A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Neurotech Pharmaceuticals. United States

• Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

  ✓ Completed Phase 2 Cell therapy

  Neurotech Pharmaceuticals. United States

• A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  Novartis Pharmaceuticals. Gene: RLBP1. Sweden

• Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema

  ✓ Completed Phase 2 Drug / neuroprotection

  Ospedale San Raffaele. Italy

• Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Cell therapy

  PT. Prodia Stem Cell Indonesia. Indonesia

• Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

  ✓ Completed Phase 1 / Phase 2 RNA / antisense

  ProQR Therapeutics. Gene: USH2A. Canada, France, United States

• Safety Study in Retinal Transplantation for Retinitis Pigmentosa.

  ✓ Completed Phase 2 Device

  Radtke, Norman D., M.D.. United States

• Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study

  Status unknown Phase 2 Drug / neuroprotection

  Rafic Hariri University Hospital

• Safety and Tolerability of hRPC in Retinitis Pigmentosa

  Status unknown Phase 1 / Phase 2 Gene therapy, Cell therapy, Retinal implant

  ReNeuron Limited. Spain, United Kingdom, United States

• DHA and X-Linked Retinitis Pigmentosa

  ✓ Completed Phase 2 Supplement / diet

  Retina Foundation of the Southwest. United States

• Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

  ■ Terminated Phase 1 / Phase 2 Gene therapy

  Sanofi. France, United States

• Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Seoul National University Hospital. South Korea

• Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa

  Status unknown Phase 2 Drug / neuroprotection

  Shahid Beheshti University of Medical Sciences. Not gene-specific. Iran

• The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil

  Status unknown Phase 1 / Phase 2 Supplement / diet, Drug / neuroprotection

  Sheba Medical Center. Israel

• Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa

  Status unknown Phase 1 / Phase 2 Cell therapy

  Stem Cells Arabia. Jordan

• Minocycline Treatment in Retinitis Pigmentosa

  ✓ Completed Phase 2 Drug / neuroprotection

  Sun Yat-sen University. China

• Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  University College, London. Gene: RPE65. United Kingdom

• Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement

  ■ Withdrawn Phase 2 Drug / neuroprotection

  University Hospital Tuebingen

• Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

  Status unknown Phase 2 Supplement / diet, Drug / neuroprotection

  University of Colorado, Denver. United States

• Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

  ■ Terminated Phase 1 / Phase 2 Drug / neuroprotection

  University of Michigan. Gene: RHO. United States

• Gene Therapy for Blindness Caused by Choroideremia

  ✓ Completed Phase 1 / Phase 2 Gene therapy

  University of Oxford. United Kingdom

• Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa

  ✓ Completed Phase 2 Cell therapy

  University of Sao Paulo. Brazil

• Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

  ■ Terminated Phase 1 / Phase 2 Gene therapy

  eyeDNA Therapeutics. Gene: PDE6B. France

• Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

  ✓ Completed Phase 1 / Phase 2 Cell therapy

  jCyte, Inc. Not gene-specific. United States

• Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

  ✓ Completed Phase 2 Cell therapy

  jCyte, Inc. Not gene-specific. United States

• Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

  ✓ Completed Phase 2 Cell therapy

  jCyte, Inc. Not gene-specific. United States

• A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

  ✓ Completed Phase 1 Drug / neuroprotection

  Abliva AB. United Kingdom

• A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

  ■ Terminated Phase 1 Gene therapy

  Centocor, Inc.. United States

• BF844 Safety and Pharmacokinetic Study in Healthy Volunteers

  Status unknown Phase 1 Drug / neuroprotection

  EyeXCel Pty. Ltd.. Australia

• Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations

  ✓ Completed Phase 1 Gene therapy

  Hadassah Medical Organization. Gene: RPE65. Israel

• Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa

  ✓ Completed Phase 1 Other

  Johns Hopkins University. United States

• The FIGHT-RP1 Study

  ✓ Completed Phase 1 Drug / neuroprotection

  Johns Hopkins University. Not gene-specific. United States

• Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)

  ✓ Completed Phase 1 Gene therapy

  King Khaled Eye Specialist Hospital. Gene: MERTK. Saudi Arabia

• Intravitreal Injection of MSCs in Retinitis Pigmentosa

  ✓ Completed Phase 1 Cell therapy

  Mahidol University. Thailand

• Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye

  ✓ Completed Phase 1 Drug / neuroprotection

  National Eye Institute (NEI). United States

• Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

  ✓ Completed Phase 1 Supplement / diet, Drug / neuroprotection

  National Eye Institute (NEI). United States

• MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

  ✓ Completed Phase 1 Drug / neuroprotection

  PYC Therapeutics. Gene: PRPF31. United States

• Stem Cells Therapy in Degenerative Diseases of the Retina

  Status unknown Phase 1 Cell therapy

  Pomeranian Medical University Szczecin. Poland

• Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

  ✓ Completed Phase 1 Drug / neuroprotection

  QLT Inc.. Gene: RPE65. Canada, Germany, Netherlands, United Kingdom and 1 more

• Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

  ✓ Completed Phase 1 Drug / neuroprotection

  QLT Inc.. Gene: RPE65. Canada, Germany, Netherlands, United Kingdom and 1 more

• Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

  ✓ Completed Phase 1 Drug / neuroprotection

  QLT Inc.. Gene: RPE65. Canada, Ireland

• Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa

  ✓ Completed Phase 1 Cell therapy

  Red de Terapia Celular. Spain

• Safety Study in Subjects With Leber Congenital Amaurosis

  ✓ Completed Phase 1 Gene therapy

  Spark Therapeutics, Inc.. Gene: RPE65. United States

• Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

  ✓ Completed Phase 1 Cell therapy

  University of California, Davis. United States

• Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

  ✓ Completed Phase 1 Gene therapy

  University of Pennsylvania. Gene: RPE65. United States

• Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa

  ✓ Completed Phase 1 Cell therapy

  University of Sao Paulo. Brazil

• Treatment of RP and LCA by Primary RPE Transplantation

  Status unknown Early Phase 1 Gene therapy

  Eyecure Therapeutics Inc.. China

• The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients

  Status unknown Early Phase 1 Drug / neuroprotection

  Hadassah Medical Organization. Israel

• Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa

  Status unknown Early Phase 1 Supplement / diet, Drug / neuroprotection

  Sun Yat-sen University. China

• Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases

  ✓ Completed N/A Drug / neuroprotection

  2C Tech Corp. Mexico

• Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)

  ■ Withdrawn N/A Drug / neuroprotection

  2C Tech Corp

• A New Treatment of Retinitis Pigmentosa

  Status unknown N/A Other

  Aier School of Ophthalmology, Central South University

• Bardet Beidle Syndrome in a Syrian Adolescent : a Rare Case Report

  Status unknown Observational Natural history / observational

  Al Baath University

• Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser

  ✓ Completed N/A Device

  Ankara Universitesi Teknokent. Turkey (Türkiye)

• Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa

  ✓ Completed N/A Drug / neuroprotection

  Ankara Universitesi Teknokent. Turkey (Türkiye)

• Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma

  ✓ Completed N/A Drug / neuroprotection

  Ankara Universitesi Teknokent

• Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.

  ✓ Completed Observational Natural history / observational

  Assistance Publique - Hôpitaux de Paris. France

• Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)

  ✓ Completed N/A Other

  Assistance Publique - Hôpitaux de Paris. France

• Development of Visual Function Evaluation Method

  ✓ Completed Observational Natural history / observational

  Astellas Pharma Inc. Japan

• Development of Visual Function Evaluation Method (2)

  ✓ Completed Observational Natural history / observational

  Astellas Pharma Inc. Japan

• Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa

  ✓ Completed N/A Other

  Azienda Policlinico Umberto I. Italy

• Structural and Functional Characterization of Rare Ocular Diseases

  Status unknown Observational Natural history / observational

  Barcelona Macula Foundation. Spain

• Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

  ✓ Completed Observational Natural history / observational

  Beacon Therapeutics. Gene: RPGR. United States

• Pilot Study of a Suprachoroidal Retinal Prosthesis

  ✓ Completed N/A Retinal implant

  Center for Eye Research Australia. Australia

• Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe

  Status unknown Observational Natural history / observational

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France, Germany, Netherlands, Portugal

• High Resolution Retina Imaging

  Status unknown Observational Natural history / observational

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Impact of Visual Field Restriction on Visual Exploration

  Status unknown Observational Natural history / observational

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Mobility Protocol Adapted for Advanced Visually Impaired Subjects

  Status unknown N/A Other

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities

  Status unknown N/A Gene therapy, Retinal implant

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Bimodal and Coaxial High Resolution Ophtalmic Imaging

  Status unknown N/A Other

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• Pupil Dynamics and Color Vision for the Detection of Eye Diseases

  ✓ Completed N/A Other

  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. France

• AUgmented REality for the Visually Impaired - Part 1

  ✓ Completed N/A Device

  Centre Hospitalier Universitaire de Nīmes. France

• Evoked Retinal Response

  ■ Terminated N/A Other

  Columbia University. United States

• CNGB1 and Allied Disorders

  ■ Suspended Observational Natural history / observational

  Columbia University. Gene: CNGB1. France, Germany, United Kingdom, United States

• SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

  ✓ Completed N/A Device

  Duke University. United States

• Natural History Study of CEP290-Related Retinal Degeneration

  ✓ Completed Observational Natural history / observational

  Editas Medicine, Inc.. Gene: CEP290. France, Germany, Netherlands, United States

• Exercise and RP (AVAMC and Emory)

  ✓ Completed N/A Other

  Emory University. United States

• Biomarkers in Retinitis Pigmentosa

  Status unknown Observational Natural history / observational

  Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Italy

• Natural History Study in Subjects With Usher Syndrome

  ✓ Completed Observational Natural history / observational

  Fondazione Telethon. Italy, Netherlands, Spain

• Study on the Effects of Mutations Under Inherited Retinal Disease in Korean

  ✓ Completed Observational Natural history / observational

  Gangnam Severance Hospital. South Korea

• Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases

  Status unknown Observational Natural history / observational

  Hillel Yaffe Medical Center

• CArotenoid in hypoChOlesterolemia

  ✓ Completed Observational Natural history / observational

  Hospices Civils de Lyon. France

• IRIS PILOT - Extended Pilot Study With a Retinal Implant System

  Status unknown N/A Retinal implant, Electrical stimulation

  Intelligent Medical Implants GmbH

• Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models

  ✓ Completed Observational Natural history / observational

  Istituto Superiore di Sanità. Italy

• An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

  ✓ Completed Observational Natural history / observational

  Janssen Pharmaceutical K.K.. Gene: RPGR. Japan

• A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

  ✓ Completed Observational Natural history / observational

  Janssen Research & Development, LLC. United States

• Stress and Vision Fluctuations in Retinitis Pigmentosa

  ✓ Completed Observational Natural history / observational

  Johns Hopkins University. United States

• Biomarkers In Retinitis Pigmentosa (BIRP)

  ✓ Completed Observational Natural history / observational

  Johns Hopkins University. United States

• Environmental Localization Mapping and Guidance for Visual Prosthesis Users

  ✓ Completed N/A Retinal implant

  Johns Hopkins University. United States

• A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa

  ■ Terminated Observational Natural history / observational

  Johns Hopkins University. United States

• Stem Cell Ophthalmology Treatment Study

  Status unknown N/A Gene therapy, Cell therapy

  MD Stem Cells. United States

• Collision Warning Device for Blind and Visually Impaired

  ✓ Completed N/A Device

  Massachusetts Eye and Ear Infirmary. United States

• Argus II/ORCAM Device Study

  ✓ Completed N/A Retinal implant

  Mayo Clinic. United States

• Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine

  ✓ Completed Observational Natural history / observational

  Mayo Clinic. United States

• Long-term Follow-up Gene Therapy Study for RPGR- XLRP

  ✓ Completed Observational Natural history / observational

  MeiraGTx Ocular UK Ltd. Gene: RPGR. United Kingdom, United States

• Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

  ✓ Completed Observational Natural history / observational

  MeiraGTx UK II Ltd. Gene: RPE65. United Kingdom, United States

• Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

  ✓ Completed Observational Natural history / observational

  MeiraGTx UK II Ltd. Gene: RPE65. United Kingdom, United States

• Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

  ✓ Completed Observational Natural history / observational

  MeiraGTx UK II Ltd. Gene: RPGR. Canada, United Kingdom, United States

• Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con>Rod Dystrophies.

  Status unknown Observational Natural history / observational

  MejoraVisionMD. Mexico

• Object Finder for a Retinal Prosthesis

  ✓ Completed N/A Retinal implant

  Minnesota HealthSolutions. United States

• Study of a Suprachoroidal Retinal Prosthesis

  ✓ Completed N/A Retinal implant

  Mobius Medical Pty Ltd.. Australia

• NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases

  ■ Terminated N/A Retinal implant

  Nano Retina. Belgium, Israel, Italy

• Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

  ✓ Completed Observational Natural history / observational

  Nanoscope Therapeutics Inc.. Puerto Rico, United States

• Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

  ■ Terminated Observational Natural history / observational

  National Center for Research Resources (NCRR). United States

• A Genetic Analysis of Usher Syndrome in Ashkenazi Jews

  ✓ Completed Observational Natural history / observational

  National Center for Research Resources (NCRR). United States

• Gyrate Atrophy of the Choroid and Retina

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Study of Usher Syndromes, Type 1 and Type 2

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Natural History and Genetic Studies of Usher Syndrome

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Molecular Genetics of Retinal Degenerations

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). China, India, Pakistan, United States

• Repository for Inherited Eye Diseases

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Potential Research Participants for Future Studies of Inherited Eye Diseases

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Color Vision as a Measure for Inherited Retinal Diseases

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

  ✓ Completed Observational Natural history / observational

  National Eye Institute (NEI). United States

• Vitamin Replacement in Abetalipoproteinemia

  ✓ Completed Observational Natural history / observational

  National Heart, Lung, and Blood Institute (NHLBI). United States

• Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

  ■ Terminated Observational Natural history / observational

  National Human Genome Research Institute (NHGRI). United States

• Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan

  ✓ Completed Observational Natural history / observational

  National Institute on Deafness and Other Communication Disorders (NIDCD). Pakistan

• Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa

  ✓ Completed Observational Natural history / observational

  National Taiwan University Hospital. Taiwan

• Natural History of the Progression of X-Linked Retinitis Pigmentosa

  ✓ Completed Observational Natural history / observational

  NightstaRx Ltd, a Biogen Company. Gene: RPGR. Canada, Finland, France, Germany and 3 more

• Expanded Access Program for RP in Adults

  Expanded access ended N/A Gene therapy

  Ocugen. Not gene-specific. United States

• Auditory Neural Function in Implanted Patients With Usher Syndrome

  ✓ Completed N/A Other

  Ohio State University. United States

• Transcorneal Electrical Stimulation Therapy for Retinal Disease

  ✓ Completed N/A Electrical stimulation

  Okuvision GmbH

• Transcorneal Electrical Stimulation - Multicenter Safety Study

  ✓ Completed N/A Electrical stimulation

  Okuvision GmbH. Denmark, Germany, Norway

• Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa

  ✓ Completed N/A Electrical stimulation

  Okuvision GmbH. Germany

• Retrospective NIS to Evaluate the Patient Benefit of TES

  ✓ Completed Observational Natural history / observational

  Okuvision GmbH. Germany, Switzerland

• Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome

  ✓ Completed Observational Natural history / observational

  Oslo University Hospital. Norway

• Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis

  ✓ Completed N/A Drug / neuroprotection

  Pierre Fabre Dermo Cosmetique. France

• In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients

  Status unknown Observational Natural history / observational

  Power Life Sciences Inc.

• Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

  ■ Withdrawn Observational Natural history / observational

  Providence Health & Services. United States

• Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

  ✓ Completed Observational Natural history / observational

  QLT Inc.. Gene: RPE65. Canada, Denmark, Germany, Netherlands and 3 more

• Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision

  ✓ Completed Observational Natural history / observational

  Queen's University, Belfast. United Kingdom

• Characterizing Rate of Progression in USHer Syndrome (CRUSH) Study

  Status unknown Observational Natural history / observational

  Radboud University Medical Center. Gene: USH2A. Netherlands

• Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

  ✓ Completed N/A Supplement / diet

  Retina Foundation of the Southwest

• Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

  ✓ Completed Observational Natural history / observational

  Retina Foundation of the Southwest. United States

• Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors

  ✓ Completed N/A Gene therapy, Retinal implant

  Retina Implant AG. Germany

• Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

  ✓ Completed N/A Gene therapy, Retinal implant

  Retina Implant AG. Germany, Hungary, United Kingdom

• Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients

  ✓ Completed N/A Gene therapy, Retinal implant

  Retina Implant AG. Hong Kong

• PMCF Study for Partial Vision Restoration Using the Subretinal Implant RETINA IMPLANT Alpha AMS

  ■ Withdrawn Observational Natural history / observational

  Retina Implant AG. Germany

• Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS

  ■ Terminated N/A Gene therapy, Retinal implant

  Retina Implant AG. France

• Microcurrent Stimulation to Treat Macular Degeneration

  ✓ Completed Observational Natural history / observational

  Retina Institute of Hawaii. United States

• An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

  Approved for marketing N/A Drug / neuroprotection

  Rhythm Pharmaceuticals, Inc.

• Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial

  ✓ Completed Observational Natural history / observational

  STZ eyetrial. Gene: PDE6A. Germany

• Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy

  ✓ Completed N/A Retinal implant

  Science Corporation. Austria, France, Germany

• Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy

  ✓ Completed N/A Retinal implant

  Science Corporation. Austria, France, Germany, Spain and 1 more

• Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa

  ✓ Completed N/A Retinal implant, Electrical stimulation

  Second Sight Medical Products. United States

• Argus® II Retinal Stimulation System Feasibility Protocol

  ✓ Completed N/A Retinal implant

  Second Sight Medical Products. France, Mexico, Switzerland, United Kingdom and 1 more

• Argus® II Retinal Prosthesis System Post-Market Surveillance Study

  ■ Terminated Observational Natural history / observational

  Second Sight Medical Products. Germany, Italy

• New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

  ■ Terminated Observational Natural history / observational

  Second Sight Medical Products. United States

• Post-Market Study of the Argus® II Retinal Prosthesis System - France

  ✓ Completed Observational Natural history / observational

  Second Sight Medical Products. France

• Argus II Retinal Prosthesis System - Better Vision RP Study

  ■ Withdrawn N/A Retinal implant

  Second Sight Medical Products. Germany

• Autoimmunity in Retinitis Pigmentosa

  Status unknown N/A Drug / neuroprotection

  Semmelweis University. Hungary

• Clinical and Genetic Testing of Patients With Usher Syndrome

  ✓ Completed Observational Natural history / observational

  Sensor Technology for Deafblind. Russia

• Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa

  ✓ Completed Observational Natural history / observational

  Sensor Technology for Deafblind. Russia

• Establishment of the National Registry for Inherited Retinal Dystrophy in Iran

  Status unknown Observational Natural history / observational

  Shahid Beheshti University of Medical Sciences. Iran

• Evaluation of Objective Perimetry Using Pupillometer

  ✓ Completed Observational Natural history / observational

  Sheba Medical Center. Israel

• The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa

  ✓ Completed N/A Supplement / diet, Drug / neuroprotection

  Sheba Medical Center. Israel

• Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)

  ■ Terminated Observational Natural history / observational

  Shire. United States

• Retrospective Natural History Study of Retinitis Pigmentosa

  Status unknown Observational Natural history / observational

  SparingVision. Gene: PDE6A, PDE6B, RHO. France

• A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

  ✓ Completed Observational Natural history / observational

  Spark Therapeutics, Inc.. Gene: RPE65. United States

• Computer-Assisted Rehabilitation Environment Training After Argus Retinal Prosthesis

  ✓ Completed N/A Retinal implant

  The Cleveland Clinic. United States

• Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum

  ✓ Completed N/A Other

  The Hong Kong Polytechnic University. Hong Kong

• The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK

  ✓ Completed Observational Natural history / observational

  The Queen Elizabeth Hospital. United Kingdom

• Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa

  ✓ Completed N/A Other

  Universidad de Granada. Spain

• Coloured-light in Retinitis Pigmentosa.

  Status unknown N/A Device

  University College, London. United Kingdom

• Observational Study of the Argus® II Retinal Prosthesis System

  Status unknown Observational Natural history / observational

  University Health Network, Toronto. Canada

• Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa

  ✓ Completed Observational Natural history / observational

  University Hospital Tuebingen. Gene: PRPF31. Germany

• ABCA4-associated Disease in Childhood and Adolescence - a Phenotype Study

  ✓ Completed Observational Natural history / observational

  University Hospital Tuebingen. Germany

• Study of New Mutations in Cone Disorders

  ■ Terminated Observational Natural history / observational

  University Hospital, Lille. France

• Evaluation of the Visual Field on the Ground

  ■ Withdrawn N/A Supplement / diet

  University Hospital, Limoges

• Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes

  ✓ Completed N/A Other

  University Hospital, Montpellier. France

• Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults

  ✓ Completed Observational Natural history / observational

  University Hospital, Strasbourg, France. Gene: BBS1. France

• Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.

  Status unknown Observational Natural history / observational

  University Hospital, Strasbourg, France. France

• Clinical Study of a Single Ciliopathy: Alström Syndrome

  ■ Terminated Observational Natural history / observational

  University Hospital, Strasbourg, France. France

• Self-confidence Study in Patients With Argus II Artificial Retina

  Status unknown Observational Natural history / observational

  University Hospital, Strasbourg, France. France

• The Perceptual Experience of Argus II Users

  ✓ Completed N/A Retinal implant

  University of California, Santa Barbara. United States

• Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene

  ✓ Completed Observational Natural history / observational

  University of Campania Luigi Vanvitelli. Gene: RPE65. Italy

• Advancing Understanding of Transportation Options

  ✓ Completed N/A Other

  University of Colorado, Denver. United States

• Visual Activity Evoked by Infrared in Humans After Dark Adaptation

  ✓ Completed N/A Other

  University of New Mexico. United States

• TES for the Treatment of RP

  ✓ Completed N/A Electrical stimulation

  University of Oxford. United Kingdom

• Visual and Functional Assessment in Low Vision Patients

  ✓ Completed Observational Natural history / observational

  University of Oxford. United Kingdom

• Safety and Efficacy of the Alpha AMS Subretinal Implant

  ✓ Completed N/A Gene therapy, Retinal implant

  University of Oxford. United Kingdom

• Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph

  ✓ Completed Observational Natural history / observational

  Visionary Intelligence Ltd.. China

• Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study

  ■ Withdrawn N/A Electrical stimulation

  Wills Eye. United States

• RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

  ■ Withdrawn N/A Gene therapy, Retinal implant

  Wills Eye. United States

• Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision

  Status unknown N/A Device

  Zhongshan Ophthalmic Center, Sun Yat-sen University. China